



Investor Presentation

Dr Adrian Kinkaid (CEO))

Disclaimer



The information contained in this document ("Presentation") has been prepared by Fusion Antibodies plc (the "Company"). The Company is a UK company quoted on AIM, a market operated by London Stock Exchange plc. This Presentation has not been fully verified and is subject to material updating, revision and further verification and amendment without notice. This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 (as amended) ("FSMA") and therefore it is being provided for information purposes only.

Allenby Capital Limited ("Allenby Capital"), which is authorised and regulated by the Financial Conduct Authority, is acting as the nominated adviser and broker to the Company. Accordingly, the recipients should note that Allenby Capital is neither advising nor treating as a client any other person and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Allenby Capital nor for providing advice in relation to the matters contained in this Presentation.

While the information contained herein has been prepared in good faith, neither the Company nor any of its directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

The views of the Company's management/directors and/or its partners set out in this document could ultimately prove to be incorrect. No warranty, express or implied, is given by the presentation of these figures here and investors should place no reliance on the Company's estimates cited in this document.

This Presentation may contain "forward-looking statements" that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, performance, financial condition, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These forward-looking statements speak only as of the date of this Presentation and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Presentation.

This Presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisers. In particular, this Presentation does not constitute or form part of any offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information or opinions contained in these slides or the Presentation or on the completeness, accuracy or fairness thereof. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.


Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.



We are established experts in preclinical antibody discovery and development CRO covering:

- Discovery
- Engineering
- Supply

We are dedicated to getting our customers to the clinic more quickly and with the best possible molecule against their target.



We work with:

- o Drug Discoverers
- o Biotech
- Virtual Companies
- Veterinary Medicine

- Diagnostic Companies
- Large Pharmaceutical Companies
- Research Institutions
- Academic Centres

Accelerating the Customer Journey

We accelerate the journey to the clinic by applying worldclass scientific expertise, rapid methodologies and nextgeneration technology including **AI/ML** in an **Integrated Therapeutic Antibody Service** to deliver the best possible antibody against a given target.



Team of internationally respected scientists, with decades of experience in bispecific and multispecific antibody design and development



Efficient, integrated approach, ensuring every decision strategically serves your end goals



Extensive knowledge and expertise, with which to de-risk development and production to accelerate program delivery



Comprehensive portfolio of antibody services, spanning discovery, engineering, and supply



Integrated Therapeutic Antibody Service,

comprehensive expertise at all stages of antibody discovery & development



AI/ML-Ab[™], combining novel AI/ML technologies with excellence in wet-lab capabilities

Full Year Trading Update (YE 31 March 2024)

- Unaudited revenues for FY2024 of £1.14m (FY2023: £2.90m)
- Increased activity in the second half of FY2024, including:
 - the entry into a collaboration agreement with the National Cancer Institute for the use of OptiMAL®;
 - a first purchase order received under a master services agreement ("MSA") with a leading diagnostics company; and
 - a follow-on project received with a US based biotechnology client.
- Fundraise announced in February 2024, raising £1.37m (before expenses) for general working capital and investment into commercial activities
- Significant increase in sales pipeline opportunities during H2 FY2024, with an orderbook at 31 March 2024 of £0.75m, representing 65 per cent. of total FY2024 unaudited revenues
- Cash position as at 31 March 2024 of £1.2m (31 March 2023: £0.2m)






Commercial Strategy to Exploit New Markets

- The Market during 2023 was adversely affected by the reduction of investment into biotechs
- Fusion revised its Commercial positioning to open new markets:
 - Diagnostics
 - Veterinary Medicine
 - Research Antibodies
 - ... and improve traction in existing market sectors especially Therapeutic biotechs
- Launched AI/ML-AbTM leveraging latest AI/ML developments for novel approaches in antibody discovery
- Launched OptiPhage[™] applying groundbreaking "Opti" technology to industry standard screening format
- Comprehensive suite of offerings which can be combined as an Integrated Therapeutic Antibody Service (ITAS)

Driving the Growth of Discovery Services







- AI/ML-AbTM discovery service launched in August 2023
- Artificial Intelligence (AI) and Machine Learning (ML) used to design novel antibodies
- These need to be brought from the virtual (in silico) into the real world: Fusion provides the wet-lab expertise to do this.
- We also have the expertise to improve on antibody sequences to make the best possible antibodies for the required purposes.
- AI/ML looks attractive as it may provide a faster and/or more cost-effective route
- Many clients looking to explore the possibilities



OptiMAL®



- Agreement with NCI (National Cancer Institute) to validate OptiMAL[®] platform announced 28th November 2023 against novel targets nominated by NCI
- Two highly advanced technologies combined:
 - The "Opti" library design: closely models the natural human Immunome
 - Hugely diverse repertoire 10⁴⁵ from which libraries of c. 10⁸-10⁹ are constructed
 - No two libraries are alike; no meaningful overlap in sequences
 - Potential for multiple licence deals
 - Principles can be applied to different species
 - Mammalian display: presenting multiple copies of a Fully intact Antibody on the surface of a Mammalian cell
 - Cell selection based on the actual antibody
 - Filters out less well-expressed antibody sequences

OptiPhageTM

- Uses the same "Opti" design (libraries) as OptiMAL[®] but packaged into Phage display format as fragments of antibodies
 - Phage is widely used in the industry and what many prospective clients are looking for
 - Prospective clients may have phage 'panning' capability already
 - Lower price point
- Unique "Opti" design can closely mimics the immunomes of standard animal hosts
 - Suitable for Rabbit, Mouse, Sheep, Goat, Dog, Cat etc.
 - No need to use animals
 - No two libraries are the same: multiple licence potential
- First OptiPhage™ contract announced April 2024




Outlook

- Improved Traction from Commercial activities
- Addressing additional complementary markets
- Improved representation:

Commercial Team increased in size Business Development consultant based in USA Increased presence at corresponding trade shows

- Significant increases in Lead Identification now converting into purchase orders received
 - Q4 revenues showed 47% increase over Q1
 - £750k Order book at start of FY24-25



Day 1 is 1st October 2023

Thank Yous

- To our Staff for their dedication, resilience, determination and attention to detail
- To our Returning clients for continuing to place their projects with us
- To our new clients in established and new sectors
- To our brokers Allenby and Shard for their support and belief
- Especially to our investors for the trust, faith and patience and recognising the potential in Fusion, providing the funds to enable us to drive the business forward despite the head winds, in order to realise that potential





What we do...

66

"One of the humanized antibodies you designed for us has excellent function and has undergone GMP production with a highly experienced CMO. According to this CMO, the antibody is the poster child for the best producing and most well-behaved antibody they have seen to date, and it will serve as the benchmark to match or exceed for their future projects.

My and OncoResponse's hats are off to you for a job well done."











Antibodies remain a leading class of therapeutics





Fig. 3 | CDER approvals by modality. Small molecules, including peptides of up to 40 amino acids in length, and oligonucleotides are approved as new molecular entities (NMEs). Protein-based candidates are approved through biologics license applications (BLAs). mAb, monoclonal antibody; siRNA, small interfering RNA. Source: *Nature Reviews Drug Discovery.*

Source: Nature Reviews Drug Discovery (2nd Jan 2024)



New Alzheimer's drugs bring hope of slowing disease for UK patients

Two dementia medicines set for approval in Britain are first to improve patients' lives directly - but condition must be diagnosed



D Evidence of Alzheimer's disease on Pet scans. Photograph: Brian Snyder/Reuters

People in Britain could benefit from a key medical breakthrough next year. They may be given access to the first drugs ever developed to slow the impact of Alzheimer's disease.

The first of these medicines - lecanemab - was recently approved in the US and Japan, where treatments using it have already been launched. A second drug, donanemab, is expected to follow soon, and next year it is anticipated that the UK medical authorities will consider both of them for approval in Britain.

The prospect has raised hopes that, after years of effort, scientists may be closing in on ways to directly tackle the UK's dementia crisis. About a million people are living with the condition in this country, and this is expected to rise to about 1.7 million by 2040 - with potentially grim consequences. Last year dementia took the lives of 66,000 people in England and Wales, and it is now the leading cause of death in Britain, with Alzheimer's accounting for two-thirds of cases.

Second antibody therapeutic shown to be viable for Alzheimer's

Source: The Observer (17th Dec 2023)